A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis

Inclusion Criteria (main): * mild to moderate stable chronic plaque-type psoriasis with at least two symmetrical lesions with a treatment area of 20 - 300 cm² and a TSS of ≥ 6; * female volunteers of childbearing potential\* must agree to use appropriate and reliable methods of contraception * written informed consent obtained. Exclusion Criteria (main): * severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis, * treatment with any locally acting medications which might counter or influence the trial aim within 2 weeks preceding the treatment phase of the trial and during the trial; * treatment with any systemic medications which might counter or influence the trial aim or phototherapy/PUVA within 4 weeks preceding the treatment phase of the trial and during the trial; * treatment with vitamin A supplements; * treatment with any biologics within 3 months preceding the treatment phase of the trial and during the trial, or in the case of ustekinumab, within 6 months; * treatment with any immunosuppressive medication within 6 months preceding the treatment phase of the trial and during the trial; * known allergic reactions, irritations or hypersensitivity to the active ingredients * contraindications according to summary of product characteristics (SmPC) of the active comparator: - pregnancy or nursing;